Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
It will open new frontier for south-to-south collaboration and innovation transfer
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator
It will showcase the company’s latest technologies in robotics, digital health and orthopaedic implants
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
Subscribe To Our Newsletter & Stay Updated
